A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Christopher R. Cogle(University of Florida), John R. Wingard(University of Florida Health), Leslie Pettiford(University of Florida), Andrés González(University of Florida), Elizabeth Wise(University of Florida), Amy Meacham(University of Florida), David Chaplin(Northwest Nazarene University), Jai Balkissoon, Randy A. Brown(University of Florida), John W. Hiemenz(University of Florida), Jack W. Hsu(University of Florida Health), Maxim Norkin(Centre Hospitalier Universitaire Vaudois)
Cited by 0
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
|Clinical Infectious Diseases|2019|2.8k
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
|Clinical Infectious Diseases|2008|2.7k